Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) initiated with Buy rating and a $12 (143% upside) price target at Nomura Instinet.
Bruker (NASDAQ:BRKR) upgraded to Overweight with a $48 (31% upside) price target at Barclays.
Danaher (NYSE:DHR) upgraded to Outperform with a $157 (21% upside) price target at RBC.
Gossamer Bio (NASDAQ:GOSS) upgraded to Outperform with an $18 (82% upside) price target at SMBC Nikko.
AMN Healthcare Services (NYSE:AMN) downgraded to Hold with a $64 (6% upside) price target at SunTrust.
Quidel (NASDAQ:QDEL) downgraded to Equal Weight with a $90 (12% upside) price target at Barclays.
https://seekingalpha.com/news/3555391-rbc-sees-21-upside-in-danaher-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.